Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review
Monoclonal TNFi are still the preferred therapeutic choice in axSpA patients with prior or high risk of uveitis. IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy.
Authors
- Elena Angeloudi (ORCID: https://orcid.org/0000-0003-3492-7915)
- Elpida Skouvaklidou (ORCID: https://orcid.org/0000-0002-0476-154X)
- Maria Boutel
- Dimitrios Deligeorgakis (ORCID: https://orcid.org/0000-0002-1379-4888)
- Paraskevi Avgerou
- N. Kougkas
- Evdokia Papadimitriou
- Christina Adamichou (ORCID: https://orcid.org/0000-0001-7374-7795)
- Ioanna Katsigianni (ORCID: https://orcid.org/0009-0002-9747-4466)
- Vasileios Skepastianos (ORCID: https://orcid.org/0009-0009-2368-7064)
- Konstantinos Tsafis (ORCID: https://orcid.org/0009-0005-3386-597X)
- Vasiliki Dimitriadou
Institutions
- Aristotle University of Thessaloniki (GR)
Publication Details
- Journal
- Mediterranean Journal of Rheumatology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.31138/mjr.310725.ect
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00